Plasma Levels of Matrix Metalloproteinases 2 and 9 in Patients with Chronic Chagas Heart Disease and Systemic Arterial Hypertension: Correlation with TGF-Beta Plasma Levels

Overview

Journal Cardiol Res Pract

Publisher Wiley

Specialty Cardiology & Vascular Diseases

Date 2023 May 1

PMID 37122872

Authors

Reinaldo B Bestetti

Renata Dellalibera-Joviliano

Ellen Rizzi

Giselle F Bonacio

Milton Faria-Jr

Rosemeire Furlan-Daniel

Suzeley Castro-Franca

Affiliations

Soon will be listed here.

Abstract

Background: Chronic Chagas heart disease (CCHD) and systemic arterial hypertension (SAH) frequently coexists in areas where Chagas disease is endemic. The effects of the association of both conditions (CCHD-SAH) on the extracellular matrix (ECM) remodeling are unknown. Matrix metalloproteinases (MMP) 2 and 9 are involved in ECM remodeling. The aim of this study was to evaluate MMP 2 and MMP9 in CCHD-SAH patients and to correlate their levels with those of the profibrogenic cytokine TGF-beta.

Methods: We included 19 patients with CCHD-SAH, 14 patients with CCHD alone, and 19 controls matched by sex and age. MMP-2 and MMP-9 plasma levels were studied by gel zymography and showed as optical densities (OD). TGF-beta plasma levels were measured by double-ligand ELISA and expressed as pg/mL.

Results: Median (5, 95) MMP-2 plasma levels were 1224.7 OD (1160, 1433.5) in patients with CCHD alone, 1424.1 OD (1267.5, 1561) in patients with CCHD-SAH, and 940 OD (898.1, 1000.8) in controls (=0.001). MMP-9 plasma levels were 1870 OD (1740, 1904.1) in patients with CCHD alone, 1754.6 OD (1650, 2049) in those with CCHD-SAH and 89.7 OD (80, 96) in controls (=0.0003). MMP-9 plasma levels were higher than those of MMP 2 in patients with CCHD-SAH (=0.01). No correlation was found between TGF-beta plasma levels with MMP-2 serum levels ( = 0.12; =0.7), but a moderate negative correlation ( = -0.46; =0.048) was observed between TGF-beta and MMP-9 plasma levels.

Conclusions: MMP-2 and especially MMP-9 may play a role in the ECM remodeling process in patients with CCHD-SAH. TGF-Beta may counteract the MMP effect on the ECM remodeling process in patients with CCHD-SAH.

References

Gurgel C, Miguel Junior A, Mendes C, Zerbini C, Carcioni T . Frequency of hypertension in chronic Chagas' disease: retrospective clinical study. Arq Bras Cardiol. 2004; 81(6):545-8, 541-4. DOI: 10.1590/s0066-782x2003001400001. View

Perez-Molina J, Molina I . Chagas disease. Lancet. 2017; 391(10115):82-94. DOI: 10.1016/S0140-6736(17)31612-4. View

Bestetti R . Role of parasites in the pathogenesis of Chagas' cardiomyopathy. Lancet. 1996; 347(9005):913-4. DOI: 10.1016/s0140-6736(96)91403-8. View

Fontana V, Silva P, Gerlach R, Tanus-Santos J . Circulating matrix metalloproteinases and their inhibitors in hypertension. Clin Chim Acta. 2012; 413(7-8):656-62. DOI: 10.1016/j.cca.2011.12.021. View

Brower G, Levick S, Janicki J . Inhibition of matrix metalloproteinase activity by ACE inhibitors prevents left ventricular remodeling in a rat model of heart failure. Am J Physiol Heart Circ Physiol. 2007; 292(6):H3057-64. DOI: 10.1152/ajpheart.00447.2006. View

Guariento M, de C Ramos M, Gontijo J, CARVALHAL S . [Chagas disease and primary arterial hypertension]. Arq Bras Cardiol. 1993; 60(2):71-5. View

Rodriguez-Angulo H, Marques J, Mendoza I, Villegas M, Mijares A, Girones N . Differential cytokine profiling in Chagasic patients according to their arrhythmogenic-status. BMC Infect Dis. 2017; 17(1):221. PMC: 5361844. DOI: 10.1186/s12879-017-2324-x. View

Bestetti R, Santos C, Ariolli M, Carmo J, Costa N, de Oliveira R . Clinical profile of patients with Chagas' disease before and during sustained ventricular tachycardia. Int J Cardiol. 1990; 29(1):39-46. DOI: 10.1016/0167-5273(90)90271-6. View

Mady C, Ianni B, Arteaga E, Montes G, Caldini E, Andrade G . Relation between interstitial myocardial collagen and the degree of clinical impairment in Chagas' disease. Am J Cardiol. 1999; 84(3):354-6, A9. DOI: 10.1016/s0002-9149(99)00295-7. View

10.

Dollery C, McEwan J, Henney A . Matrix metalloproteinases and cardiovascular disease. Circ Res. 1995; 77(5):863-8. DOI: 10.1161/01.res.77.5.863. View

11.

Araujo-Jorge T, Waghabi M, Hasslocher-Moreno A, Xavier S, Higuchi M, Keramidas M . Implication of transforming growth factor-beta1 in Chagas disease myocardiopathy. J Infect Dis. 2002; 186(12):1823-8. DOI: 10.1086/345882. View

12.

Garcia-Saldivia M, Lopez-Mendez G, Berrueta L, Salmen S, Donis J, Davila D . Left ventricular geometry and matrix metalloproteinases 2 and 9 in chronic Chagas heart disease. Int J Cardiol. 2014; 176(2):565-6. DOI: 10.1016/j.ijcard.2014.07.009. View

13.

Bestetti R, Ariolli M, do Carmo J, Passos A, Santos C, Machado Junior O . Clinical characteristics of acute myocardial infarction in patients with Chagas' disease. Int J Cardiol. 1992; 35(3):371-6. DOI: 10.1016/0167-5273(92)90236-v. View

14.

de Boer R, De Keulenaer G, Bauersachs J, Brutsaert D, Cleland J, Diez J . Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. Eur J Heart Fail. 2019; 21(3):272-285. PMC: 6607480. DOI: 10.1002/ejhf.1406. View

15.

Felker G, Thompson R, Hare J, Hruban R, Clemetson D, Howard D . Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000; 342(15):1077-84. DOI: 10.1056/NEJM200004133421502. View

16.

Cojan-Minzat B, Zlibut A, Agoston-Coldea L . Non-ischemic dilated cardiomyopathy and cardiac fibrosis. Heart Fail Rev. 2020; 26(5):1081-1101. DOI: 10.1007/s10741-020-09940-0. View

17.

Baroldi G, Oliveira S, Silver M . Sudden and unexpected death in clinically 'silent' Chagas' disease. A hypothesis. Int J Cardiol. 1997; 58(3):263-8. DOI: 10.1016/s0167-5273(96)02878-1. View

18.

George J, Patal S, Wexler D, Roth A, Sheps D, Keren G . Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. Am Heart J. 2005; 150(3):484-7. DOI: 10.1016/j.ahj.2004.11.016. View

19.

Demacq C, de Souza A, Machado A, Gerlach R, Tanus-Santos J . Genetic polymorphism of matrix metalloproteinase (MMP)-9 does not affect plasma MMP-9 activity in healthy subjects. Clin Chim Acta. 2005; 365(1-2):183-7. DOI: 10.1016/j.cca.2005.08.017. View

20.

Bern C . Chagas' Disease. N Engl J Med. 2015; 373(5):456-66. DOI: 10.1056/NEJMra1410150. View